Latest News - Retina

Monday, October 02, 2017 | Clinical Trials, Retina

Efficacy Data on Novel Treatment for Diabetic Macular Edema

Verseon presented promising preclinical efficacy results on its plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME) at the fifth annual Targeting Ocular Disorders conference…

Read the full story

Monday, October 02, 2017 | Medical Studies, Retina

Eyedrops for Diabetic Retinopathy Possible in the Future?

Early topical treatment for diabetic retinopathy may be possible in the future, at least for a subset of diabetes patients, new trial results suggest, according to a report in Medscape. Findings fr…

Read the full story

Friday, September 29, 2017 | Medical Studies, Retina

Low LDL Target Resulted in No Clinical Gain in Non-CAD Diabetes: EMPATHY

Cardiovascular risk did not drop significantly over 3 years with intensive statin therapy, compared with a standard statin regimen, in a randomized trial that entered only dyslipidemic patients with d…

Read the full story

Thursday, September 28, 2017 | Clinical Trials, Retina

First Patient in US Receives a Telescope Implant for Age-Related Macular Degeneration After Previous Cataract Surgery

VisionCare announced that the first patient in its clinical investigation to evaluate the safety and effectiveness of exchanging a previously implanted IOL with the Implantable Miniature Telescope (by…

Read the full story

Tuesday, September 19, 2017 | Clinical Trials, Retina, AMD, GrayBug

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet AMD

Graybug Vision announced that it has begun dosing patients with wet AMD in its first clinical trial of GB-102, its lead product. GB-102 is a novel intravitreal (IVT) injectable depot formulation of su…

Read the full story

Tuesday, September 19, 2017 | Clinical Trials, Retina, Ophthotech

Ophthotech Provides Update on Zimura Complement Programs for Treatment of Eye Diseases

Ophthotech announced the initiation of an open-label phase 2a clinical trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, in patients with wet age-related macula…

Read the full story

Tuesday, September 19, 2017 | Medical Studies, Retina

Laser May Be Safer Than Bevacizumab in Babies With Acute-Phase ROP

Babies with acute-phase retinopathy of prematurity (ROP) who are treated with bevacizumab have more long-term eye problems than babies treated with laser, according to a new randomized controlled tria…

Read the full story

Monday, September 11, 2017 | Retina, Alimera Sciences

Illuvien Now Available in Ireland for the Treatment of Chronic DME

Iluvien (190µg fluocinolone acetonide (FAc) intravitreal implant in applicator) is being made available in Ireland following an agreement between the healthcare provider Vhi and Iluvien’s …

Read the full story

Monday, September 11, 2017 | Clinical Trials, Retina, AMD, Genentech

Genentech's Lampalizumab Fails Phase 3 Study for Geographic Atrophy

Genentech announced that the primary endpoint has not been met in Spectri, the first of two phase 3 studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the trea…

Read the full story

Monday, September 11, 2017 | Medical Studies, Retina

Ranibizumab Beats Laser for Diabetic Retinopathy

Ranibizumab treats proliferative diabetic retinopathy more effectively than laser photocoagulation, researchers reported at the 17th EURETINA Congress. The finding challenges lasers as the standard of…

Read the full story

Monday, September 11, 2017 | Medical Studies, Retina

Retina Specialists Seek to Stem Myopia Epidemic

In light of the increasing prevalence of myopia in certain parts of the world, ophthalmologists should advise parents on ways to curb the development of myopia in children and intervene early if myopi…

Read the full story

Friday, September 01, 2017 | Retina, Genentech

EURETINA 2017: Genentech Ophthalmology Data Highlights

Genentech released teh data it will be presenting at the European Society of Retina Specialists (EURETINA) meeting on September 7-10 in Barcelona. Below are key takeaways from the EURETINA 2017 stu…

Read the full story

Friday, September 01, 2017 | Earnings & Financials, Retina, NightstaRx

Nightstar Files Registration Statement For Proposed Initial Public Offering

Nightstar Therapeutics a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, announced that it has filed a registration statement on Form F-1 with the U.S. S…

Read the full story

Friday, September 01, 2017 | Retina

Vision Gains From Aflibercept for Diabetic Macular Edema Persist for 5 Years

As-needed aflibercept treatment maintains vision gains in patients with diabetic macular edema (DME) through 5 years of treatment, even with reduced aflibercept dosing in the later years, according to…

Read the full story

Monday, August 28, 2017 | Clinical Trials, Retina, Second Sight Medical Products

Second Sight Receives Conditional FDA Approval to Begin First Orion Human Clinical Study

Second Sight Medical Products announced that it has received conditional approval from the FDA to begin the Orion Cortical Visual Prosthesis System feasibility clinical study. The conditional approval…

Read the full story
Load More